0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cancer Immunotherapies Market Insights, Forecast to 2029
Published Date: June 2023
|
Report Code: QYRE-Auto-37N14618
Home | Market Reports | Health| Health Conditions| Cancer
Global Cancer Immunotherapies Market Insights Forecast to 2029
BUY CHAPTERS

Global Cancer Immunotherapies Market Insights, Forecast to 2029

Code: QYRE-Auto-37N14618
Report
June 2023
Pages:109
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cancer Immunotherapies Market

Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.
The global Cancer Immunotherapies market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Cancer Immunotherapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Cancer Immunotherapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Cancer Immunotherapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of Cancer Immunotherapies include Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis and Pfizer, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes:

This report presents an overview of global market for Cancer Immunotherapies, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Cancer Immunotherapies, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Cancer Immunotherapies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cancer Immunotherapies sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Cancer Immunotherapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Cancer Immunotherapies sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis and Pfizer, etc.

Scope of Cancer Immunotherapies Market Report

Report Metric Details
Report Name Cancer Immunotherapies Market
Segment by Type
  • Monoclonal Antibodies (MABs)
  • Cancer Vaccines
  • Immunomodulators
  • Adoptive Cell transfer
  • Checkpoint Inhibitors
Segment by Application
  • Breast Cancer
  • Leukemia
  • Lymphoma
  • Melanoma
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
Segment by Region
  • US & Canada
  • U.S.
  • Canada
  • China
  • Asia (excluding China)
  • Japan
  • South Korea
  • China Taiwan
  • Southeast Asia
  • India
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Middle East, Africa, Latin America
  • Brazil
  • Mexico
  • Turkey
  • Israel
  • GCC Countries
By Company Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis, Pfizer, Johnson & Johnson, AbbVie, Gilead Sciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Cancer Immunotherapies in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 3: Detailed analysis of Cancer Immunotherapies manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
  • Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
  • Chapter 8: China by type, by application sales and revenue for each segment.
  • Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
  • Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Immunotherapies sales, revenue, price, gross margin, and recent development, etc.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Cancer Immunotherapies Product Introduction
1.2 Market by Type
1.2.1 Global Cancer Immunotherapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies (MABs)
1.2.3 Cancer Vaccines
1.2.4 Immunomodulators
1.2.5 Adoptive Cell transfer
1.2.6 Checkpoint Inhibitors
1.3 Market by Application
1.3.1 Global Cancer Immunotherapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Melanoma
1.3.6 Colorectal Cancer
1.3.7 Non-Small Cell Lung Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cancer Immunotherapies Sales Estimates and Forecasts 2018-2029
2.2 Global Cancer Immunotherapies Revenue by Region
2.2.1 Global Cancer Immunotherapies Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Cancer Immunotherapies Revenue by Region (2018-2023)
2.2.3 Global Cancer Immunotherapies Revenue by Region (2024-2029)
2.2.4 Global Cancer Immunotherapies Revenue Market Share by Region (2018-2029)
2.3 Global Cancer Immunotherapies Sales Estimates and Forecasts 2018-2029
2.4 Global Cancer Immunotherapies Sales by Region
2.4.1 Global Cancer Immunotherapies Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Cancer Immunotherapies Sales by Region (2018-2023)
2.4.3 Global Cancer Immunotherapies Sales by Region (2024-2029)
2.4.4 Global Cancer Immunotherapies Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Cancer Immunotherapies Sales by Manufacturers
3.1.1 Global Cancer Immunotherapies Sales by Manufacturers (2018-2023)
3.1.2 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Immunotherapies in 2022
3.2 Global Cancer Immunotherapies Revenue by Manufacturers
3.2.1 Global Cancer Immunotherapies Revenue by Manufacturers (2018-2023)
3.2.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Immunotherapies Revenue in 2022
3.3 Global Key Players of Cancer Immunotherapies, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Cancer Immunotherapies Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cancer Immunotherapies, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cancer Immunotherapies, Product Offered and Application
3.8 Global Key Manufacturers of Cancer Immunotherapies, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cancer Immunotherapies Sales by Type
4.1.1 Global Cancer Immunotherapies Historical Sales by Type (2018-2023)
4.1.2 Global Cancer Immunotherapies Forecasted Sales by Type (2024-2029)
4.1.3 Global Cancer Immunotherapies Sales Market Share by Type (2018-2029)
4.2 Global Cancer Immunotherapies Revenue by Type
4.2.1 Global Cancer Immunotherapies Historical Revenue by Type (2018-2023)
4.2.2 Global Cancer Immunotherapies Forecasted Revenue by Type (2024-2029)
4.2.3 Global Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
4.3 Global Cancer Immunotherapies Price by Type
4.3.1 Global Cancer Immunotherapies Price by Type (2018-2023)
4.3.2 Global Cancer Immunotherapies Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Cancer Immunotherapies Sales by Application
5.1.1 Global Cancer Immunotherapies Historical Sales by Application (2018-2023)
5.1.2 Global Cancer Immunotherapies Forecasted Sales by Application (2024-2029)
5.1.3 Global Cancer Immunotherapies Sales Market Share by Application (2018-2029)
5.2 Global Cancer Immunotherapies Revenue by Application
5.2.1 Global Cancer Immunotherapies Historical Revenue by Application (2018-2023)
5.2.2 Global Cancer Immunotherapies Forecasted Revenue by Application (2024-2029)
5.2.3 Global Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
5.3 Global Cancer Immunotherapies Price by Application
5.3.1 Global Cancer Immunotherapies Price by Application (2018-2023)
5.3.2 Global Cancer Immunotherapies Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Cancer Immunotherapies Market Size by Type
6.1.1 US & Canada Cancer Immunotherapies Sales by Type (2018-2029)
6.1.2 US & Canada Cancer Immunotherapies Revenue by Type (2018-2029)
6.2 US & Canada Cancer Immunotherapies Market Size by Application
6.2.1 US & Canada Cancer Immunotherapies Sales by Application (2018-2029)
6.2.2 US & Canada Cancer Immunotherapies Revenue by Application (2018-2029)
6.3 US & Canada Cancer Immunotherapies Market Size by Country
6.3.1 US & Canada Cancer Immunotherapies Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Cancer Immunotherapies Sales by Country (2018-2029)
6.3.3 US & Canada Cancer Immunotherapies Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Cancer Immunotherapies Market Size by Type
7.1.1 Europe Cancer Immunotherapies Sales by Type (2018-2029)
7.1.2 Europe Cancer Immunotherapies Revenue by Type (2018-2029)
7.2 Europe Cancer Immunotherapies Market Size by Application
7.2.1 Europe Cancer Immunotherapies Sales by Application (2018-2029)
7.2.2 Europe Cancer Immunotherapies Revenue by Application (2018-2029)
7.3 Europe Cancer Immunotherapies Market Size by Country
7.3.1 Europe Cancer Immunotherapies Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Cancer Immunotherapies Sales by Country (2018-2029)
7.3.3 Europe Cancer Immunotherapies Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Cancer Immunotherapies Market Size
8.1.1 China Cancer Immunotherapies Sales (2018-2029)
8.1.2 China Cancer Immunotherapies Revenue (2018-2029)
8.2 China Cancer Immunotherapies Market Size by Application
8.2.1 China Cancer Immunotherapies Sales by Application (2018-2029)
8.2.2 China Cancer Immunotherapies Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cancer Immunotherapies Market Size by Type
9.1.1 Asia Cancer Immunotherapies Sales by Type (2018-2029)
9.1.2 Asia Cancer Immunotherapies Revenue by Type (2018-2029)
9.2 Asia Cancer Immunotherapies Market Size by Application
9.2.1 Asia Cancer Immunotherapies Sales by Application (2018-2029)
9.2.2 Asia Cancer Immunotherapies Revenue by Application (2018-2029)
9.3 Asia Cancer Immunotherapies Sales by Region
9.3.1 Asia Cancer Immunotherapies Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Cancer Immunotherapies Revenue by Region (2018-2029)
9.3.3 Asia Cancer Immunotherapies Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cancer Immunotherapies Market Size by Type
10.1.1 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Cancer Immunotherapies Market Size by Application
10.2.1 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country
10.3.1 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Amgen Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 AstraZeneca Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Overview
11.3.3 Roche Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Roche Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Roche Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb Overview
11.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Overview
11.5.3 Bayer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Bayer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bayer Recent Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Overview
11.6.3 Merck Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Merck Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Merck Recent Developments
11.7 ARMO BioSciences (Eli Lilly)
11.7.1 ARMO BioSciences (Eli Lilly) Company Information
11.7.2 ARMO BioSciences (Eli Lilly) Overview
11.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 ARMO BioSciences (Eli Lilly) Recent Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Overview
11.8.3 Novartis Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Novartis Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Overview
11.9.3 Pfizer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Pfizer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pfizer Recent Developments
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Information
11.10.2 Johnson & Johnson Overview
11.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Johnson & Johnson Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Johnson & Johnson Recent Developments
11.11 AbbVie
11.11.1 AbbVie Company Information
11.11.2 AbbVie Overview
11.11.3 AbbVie Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 AbbVie Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AbbVie Recent Developments
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Information
11.12.2 Gilead Sciences Overview
11.12.3 Gilead Sciences Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Gilead Sciences Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Gilead Sciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cancer Immunotherapies Industry Chain Analysis
12.2 Cancer Immunotherapies Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Immunotherapies Production Mode & Process
12.4 Cancer Immunotherapies Sales and Marketing
12.4.1 Cancer Immunotherapies Sales Channels
12.4.2 Cancer Immunotherapies Distributors
12.5 Cancer Immunotherapies Customers
13 Market Dynamics
13.1 Cancer Immunotherapies Industry Trends
13.2 Cancer Immunotherapies Market Drivers
13.3 Cancer Immunotherapies Market Challenges
13.4 Cancer Immunotherapies Market Restraints
14 Key Findings in The Global Cancer Immunotherapies Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Cancer Immunotherapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Table 2. Major Manufacturers of Monoclonal Antibodies (MABs)
    Table 3. Major Manufacturers of Cancer Vaccines
    Table 4. Major Manufacturers of Immunomodulators
    Table 5. Major Manufacturers of Adoptive Cell transfer
    Table 6. Major Manufacturers of Checkpoint Inhibitors
    Table 7. Global Cancer Immunotherapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Table 8. Global Cancer Immunotherapies Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 9. Global Cancer Immunotherapies Revenue by Region (2018-2023) & (US$ Million)
    Table 10. Global Cancer Immunotherapies Revenue by Region (2024-2029) & (US$ Million)
    Table 11. Global Cancer Immunotherapies Revenue Market Share by Region (2018-2023)
    Table 12. Global Cancer Immunotherapies Revenue Market Share by Region (2024-2029)
    Table 13. Global Cancer Immunotherapies Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 14. Global Cancer Immunotherapies Sales by Region (2018-2023) & (K Units)
    Table 15. Global Cancer Immunotherapies Sales by Region (2024-2029) & (K Units)
    Table 16. Global Cancer Immunotherapies Sales Market Share by Region (2018-2023)
    Table 17. Global Cancer Immunotherapies Sales Market Share by Region (2024-2029)
    Table 18. Global Cancer Immunotherapies Sales by Manufacturers (2018-2023) & (K Units)
    Table 19. Global Cancer Immunotherapies Sales Share by Manufacturers (2018-2023)
    Table 20. Global Cancer Immunotherapies Revenue by Manufacturers (2018-2023) & (US$ Million)
    Table 21. Global Cancer Immunotherapies Revenue Share by Manufacturers (2018-2023)
    Table 22. Global Key Players of Cancer Immunotherapies, Industry Ranking, 2021 VS 2022 VS 2023
    Table 23. Cancer Immunotherapies Price by Manufacturers 2018-2023 (USD/Unit)
    Table 24. Global Cancer Immunotherapies Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 25. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2022)
    Table 26. Global Key Manufacturers of Cancer Immunotherapies, Manufacturing Base Distribution and Headquarters
    Table 27. Global Key Manufacturers of Cancer Immunotherapies, Product Offered and Application
    Table 28. Global Key Manufacturers of Cancer Immunotherapies, Date of Enter into This Industry
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
    Table 31. Global Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
    Table 32. Global Cancer Immunotherapies Sales Share by Type (2018-2023)
    Table 33. Global Cancer Immunotherapies Sales Share by Type (2024-2029)
    Table 34. Global Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
    Table 35. Global Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
    Table 36. Global Cancer Immunotherapies Revenue Share by Type (2018-2023)
    Table 37. Global Cancer Immunotherapies Revenue Share by Type (2024-2029)
    Table 38. Cancer Immunotherapies Price by Type (2018-2023) & (USD/Unit)
    Table 39. Global Cancer Immunotherapies Price Forecast by Type (2024-2029) & (USD/Unit)
    Table 40. Global Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
    Table 41. Global Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
    Table 42. Global Cancer Immunotherapies Sales Share by Application (2018-2023)
    Table 43. Global Cancer Immunotherapies Sales Share by Application (2024-2029)
    Table 44. Global Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
    Table 45. Global Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
    Table 46. Global Cancer Immunotherapies Revenue Share by Application (2018-2023)
    Table 47. Global Cancer Immunotherapies Revenue Share by Application (2024-2029)
    Table 48. Cancer Immunotherapies Price by Application (2018-2023) & (USD/Unit)
    Table 49. Global Cancer Immunotherapies Price Forecast by Application (2024-2029) & (USD/Unit)
    Table 50. US & Canada Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
    Table 51. US & Canada Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
    Table 52. US & Canada Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
    Table 53. US & Canada Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
    Table 54. US & Canada Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
    Table 55. US & Canada Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
    Table 56. US & Canada Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
    Table 57. US & Canada Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
    Table 58. US & Canada Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 59. US & Canada Cancer Immunotherapies Revenue by Country (2018-2023) & (US$ Million)
    Table 60. US & Canada Cancer Immunotherapies Revenue by Country (2024-2029) & (US$ Million)
    Table 61. US & Canada Cancer Immunotherapies Sales by Country (2018-2023) & (K Units)
    Table 62. US & Canada Cancer Immunotherapies Sales by Country (2024-2029) & (K Units)
    Table 63. Europe Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
    Table 64. Europe Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
    Table 65. Europe Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
    Table 66. Europe Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
    Table 67. Europe Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
    Table 68. Europe Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
    Table 69. Europe Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
    Table 70. Europe Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
    Table 71. Europe Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 72. Europe Cancer Immunotherapies Revenue by Country (2018-2023) & (US$ Million)
    Table 73. Europe Cancer Immunotherapies Revenue by Country (2024-2029) & (US$ Million)
    Table 74. Europe Cancer Immunotherapies Sales by Country (2018-2023) & (K Units)
    Table 75. Europe Cancer Immunotherapies Sales by Country (2024-2029) & (K Units)
    Table 76. China Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
    Table 77. China Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
    Table 78. China Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
    Table 79. China Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
    Table 80. China Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
    Table 81. China Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
    Table 82. China Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
    Table 83. China Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
    Table 84. Asia Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
    Table 85. Asia Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
    Table 86. Asia Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
    Table 87. Asia Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
    Table 88. Asia Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
    Table 89. Asia Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
    Table 90. Asia Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
    Table 91. Asia Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
    Table 92. Asia Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 93. Asia Cancer Immunotherapies Revenue by Region (2018-2023) & (US$ Million)
    Table 94. Asia Cancer Immunotherapies Revenue by Region (2024-2029) & (US$ Million)
    Table 95. Asia Cancer Immunotherapies Sales by Region (2018-2023) & (K Units)
    Table 96. Asia Cancer Immunotherapies Sales by Region (2024-2029) & (K Units)
    Table 97. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
    Table 98. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
    Table 99. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
    Table 100. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
    Table 102. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
    Table 103. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 106. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country (2018-2023) & (US$ Million)
    Table 107. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country (2024-2029) & (US$ Million)
    Table 108. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country (2018-2023) & (K Units)
    Table 109. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country (2024-2029) & (K Units)
    Table 110. Amgen Company Information
    Table 111. Amgen Description and Major Businesses
    Table 112. Amgen Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 113. Amgen Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Amgen Recent Developments
    Table 115. AstraZeneca Company Information
    Table 116. AstraZeneca Description and Major Businesses
    Table 117. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 118. AstraZeneca Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. AstraZeneca Recent Developments
    Table 120. Roche Company Information
    Table 121. Roche Description and Major Businesses
    Table 122. Roche Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 123. Roche Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Roche Recent Developments
    Table 125. Bristol-Myers Squibb Company Information
    Table 126. Bristol-Myers Squibb Description and Major Businesses
    Table 127. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 128. Bristol-Myers Squibb Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Bristol-Myers Squibb Recent Developments
    Table 130. Bayer Company Information
    Table 131. Bayer Description and Major Businesses
    Table 132. Bayer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 133. Bayer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Bayer Recent Developments
    Table 135. Merck Company Information
    Table 136. Merck Description and Major Businesses
    Table 137. Merck Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 138. Merck Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Merck Recent Developments
    Table 140. ARMO BioSciences (Eli Lilly) Company Information
    Table 141. ARMO BioSciences (Eli Lilly) Description and Major Businesses
    Table 142. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 143. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. ARMO BioSciences (Eli Lilly) Recent Developments
    Table 145. Novartis Company Information
    Table 146. Novartis Description and Major Businesses
    Table 147. Novartis Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 148. Novartis Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Novartis Recent Developments
    Table 150. Pfizer Company Information
    Table 151. Pfizer Description and Major Businesses
    Table 152. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 153. Pfizer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 154. Pfizer Recent Developments
    Table 155. Johnson & Johnson Company Information
    Table 156. Johnson & Johnson Description and Major Businesses
    Table 157. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 158. Johnson & Johnson Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 159. Johnson & Johnson Recent Developments
    Table 160. AbbVie Company Information
    Table 161. AbbVie Description and Major Businesses
    Table 162. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 163. AbbVie Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 164. AbbVie Recent Developments
    Table 165. Gilead Sciences Company Information
    Table 166. Gilead Sciences Description and Major Businesses
    Table 167. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 168. Gilead Sciences Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
    Table 169. Gilead Sciences Recent Developments
    Table 170. Key Raw Materials Lists
    Table 171. Raw Materials Key Suppliers Lists
    Table 172. Cancer Immunotherapies Distributors List
    Table 173. Cancer Immunotherapies Customers List
    Table 174. Cancer Immunotherapies Market Trends
    Table 175. Cancer Immunotherapies Market Drivers
    Table 176. Cancer Immunotherapies Market Challenges
    Table 177. Cancer Immunotherapies Market Restraints
    Table 178. Research Programs/Design for This Report
    Table 179. Key Data Information from Secondary Sources
    Table 180. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cancer Immunotherapies Product Picture
    Figure 2. Global Cancer Immunotherapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 3. Global Cancer Immunotherapies Market Share by Type in 2022 & 2029
    Figure 4. Monoclonal Antibodies (MABs) Product Picture
    Figure 5. Cancer Vaccines Product Picture
    Figure 6. Immunomodulators Product Picture
    Figure 7. Adoptive Cell transfer Product Picture
    Figure 8. Checkpoint Inhibitors Product Picture
    Figure 9. Global Cancer Immunotherapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 10. Global Cancer Immunotherapies Market Share by Application in 2022 & 2029
    Figure 11. Breast Cancer
    Figure 12. Leukemia
    Figure 13. Lymphoma
    Figure 14. Melanoma
    Figure 15. Colorectal Cancer
    Figure 16. Non-Small Cell Lung Cancer
    Figure 17. Cancer Immunotherapies Report Years Considered
    Figure 18. Global Cancer Immunotherapies Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 19. Global Cancer Immunotherapies Revenue 2018-2029 (US$ Million)
    Figure 20. Global Cancer Immunotherapies Revenue Market Share by Region in Percentage: 2022 Versus 2029
    Figure 21. Global Cancer Immunotherapies Revenue Market Share by Region (2018-2029)
    Figure 22. Global Cancer Immunotherapies Sales 2018-2029 ((K Units)
    Figure 23. Global Cancer Immunotherapies Sales Market Share by Region (2018-2029)
    Figure 24. US & Canada Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
    Figure 25. US & Canada Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
    Figure 26. Europe Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
    Figure 27. Europe Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
    Figure 28. China Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
    Figure 29. China Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
    Figure 30. Asia (excluding China) Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
    Figure 31. Asia (excluding China) Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
    Figure 32. Middle East, Africa and Latin America Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
    Figure 33. Middle East, Africa and Latin America Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
    Figure 34. The Cancer Immunotherapies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
    Figure 35. The Top 5 and 10 Largest Manufacturers of Cancer Immunotherapies in the World: Market Share by Cancer Immunotherapies Revenue in 2022
    Figure 36. Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
    Figure 37. Global Cancer Immunotherapies Sales Market Share by Type (2018-2029)
    Figure 38. Global Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
    Figure 39. Global Cancer Immunotherapies Sales Market Share by Application (2018-2029)
    Figure 40. Global Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
    Figure 41. US & Canada Cancer Immunotherapies Sales Market Share by Type (2018-2029)
    Figure 42. US & Canada Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
    Figure 43. US & Canada Cancer Immunotherapies Sales Market Share by Application (2018-2029)
    Figure 44. US & Canada Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
    Figure 45. US & Canada Cancer Immunotherapies Revenue Share by Country (2018-2029)
    Figure 46. US & Canada Cancer Immunotherapies Sales Share by Country (2018-2029)
    Figure 47. U.S. Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 48. Canada Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 49. Europe Cancer Immunotherapies Sales Market Share by Type (2018-2029)
    Figure 50. Europe Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
    Figure 51. Europe Cancer Immunotherapies Sales Market Share by Application (2018-2029)
    Figure 52. Europe Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
    Figure 53. Europe Cancer Immunotherapies Revenue Share by Country (2018-2029)
    Figure 54. Europe Cancer Immunotherapies Sales Share by Country (2018-2029)
    Figure 55. Germany Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 56. France Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 57. U.K. Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 58. Italy Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 59. Russia Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 60. China Cancer Immunotherapies Sales Market Share by Type (2018-2029)
    Figure 61. China Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
    Figure 62. China Cancer Immunotherapies Sales Market Share by Application (2018-2029)
    Figure 63. China Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
    Figure 64. Asia Cancer Immunotherapies Sales Market Share by Type (2018-2029)
    Figure 65. Asia Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
    Figure 66. Asia Cancer Immunotherapies Sales Market Share by Application (2018-2029)
    Figure 67. Asia Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
    Figure 68. Asia Cancer Immunotherapies Revenue Share by Region (2018-2029)
    Figure 69. Asia Cancer Immunotherapies Sales Share by Region (2018-2029)
    Figure 70. Japan Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 71. South Korea Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 72. China Taiwan Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 73. Southeast Asia Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 74. India Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 75. Middle East, Africa and Latin America Cancer Immunotherapies Sales Market Share by Type (2018-2029)
    Figure 76. Middle East, Africa and Latin America Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
    Figure 77. Middle East, Africa and Latin America Cancer Immunotherapies Sales Market Share by Application (2018-2029)
    Figure 78. Middle East, Africa and Latin America Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
    Figure 79. Middle East, Africa and Latin America Cancer Immunotherapies Revenue Share by Country (2018-2029)
    Figure 80. Middle East, Africa and Latin America Cancer Immunotherapies Sales Share by Country (2018-2029)
    Figure 81. Brazil Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 82. Mexico Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 83. Turkey Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 84. Israel Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 85. GCC Countries Cancer Immunotherapies Revenue (2018-2029) & (US$ Million)
    Figure 86. Cancer Immunotherapies Value Chain
    Figure 87. Cancer Immunotherapies Production Process
    Figure 88. Channels of Distribution
    Figure 89. Distributors Profiles
    Figure 90. Bottom-up and Top-down Approaches for This Report
    Figure 91. Data Triangulation
    Figure 92. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Gene Therapy For Cancer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-22G13317
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Cancer Biomarkers Detection Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-30Q5590
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Oncology Companion Diagnostic Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14K8500
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Throat Cancer Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-8R8713
Fri Feb 23 00:00:00 UTC 2024

Add to Cart